Company
Novo Nordisk
NYSE:NVO
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
220 stories · page 2 of 3
Novo Nordisk to release clinical update on star drug Wegovy
Results from the SELECT study will be presented at the American Heart Association (AHA) conference on November 11.
Novo Nordisk buys blood pressure treatment to bolster diabetes portfolio
Novo is paying KBP Biosciences US$1.3 billion for ocedurenone
Novo Nordisk Wegovy surge to continue, says Stifel
Novo Nordisk delivered 30% and 32% growth in sales and operating income respectively in the first half